145 related articles for article (PubMed ID: 10716467)
1. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
[TBL] [Abstract][Full Text] [Related]
2. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
[TBL] [Abstract][Full Text] [Related]
3. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
[TBL] [Abstract][Full Text] [Related]
4. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
[TBL] [Abstract][Full Text] [Related]
5. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
[TBL] [Abstract][Full Text] [Related]
6. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Hamsten A; Nilsson J
Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
[TBL] [Abstract][Full Text] [Related]
7. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson CG
Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
[TBL] [Abstract][Full Text] [Related]
8. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).
Ericsson CG; Nilsson J; Grip L; Svane B; Hamsten A
Am J Cardiol; 1997 Nov; 80(9):1125-9. PubMed ID: 9359536
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
10. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
Yoshino G; Hirano T; Kazumi T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
[No Abstract] [Full Text] [Related]
11. Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls.
Anastasilakis AD; Koulaxis D; Upadhyay J; Pagkalidou E; Kefala N; Perakakis N; Polyzos SA; Economou F; Mantzoros CS
Horm Metab Res; 2019 Feb; 51(2):112-119. PubMed ID: 30497090
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.
Node K; Inoue T; Boyko V; Goldberg I; Fisman EZ; Adler Y; Schwammenthal E; Matas Z; Behar S; Tenenbaum A
Cardiovasc Diabetol; 2009 Jan; 8():5. PubMed ID: 19173749
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
Tenenbaum A; Fisman EZ; Boyko V; Benderly M; Tanne D; Haim M; Matas Z; Motro M; Behar S
Arch Intern Med; 2006 Apr; 166(7):737-41. PubMed ID: 16606809
[TBL] [Abstract][Full Text] [Related]
14. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures.
Benbassat CA; Maki KC; Unterman TG
J Clin Endocrinol Metab; 1997 May; 82(5):1484-91. PubMed ID: 9141538
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Jovinge S; Hamsten A; Tornvall P; Proudler A; Båvenholm P; Ericsson CG; Godsland I; de Faire U; Nilsson J
Metabolism; 1998 Jan; 47(1):113-8. PubMed ID: 9440488
[TBL] [Abstract][Full Text] [Related]
17. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
[TBL] [Abstract][Full Text] [Related]
18. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Jonkers IJ; Mohrschladt MF; Westendorp RG; van der Laarse A; Smelt AH
Am J Med; 2002 Mar; 112(4):275-80. PubMed ID: 11893366
[TBL] [Abstract][Full Text] [Related]
19. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Elkeles RS; Diamond JR; Poulter C; Dhanjil S; Nicolaides AN; Mahmood S; Richmond W; Mather H; Sharp P; Feher MD
Diabetes Care; 1998 Apr; 21(4):641-8. PubMed ID: 9571357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
